Certain codes in your summary statement can indicate an award restriction or bar to award, which can block you from funding until you resolve underlying scientific review concerns about human subjects involvement, inclusion, or animal welfare.
NIAID seeks collaborative, global research focused on the etiology, epidemiology, pathogenesis, clinical manifestations, diagnosis, prevention, treatment, and control of select neglected tropical diseases.
NIAID aims to promote research-driven data science/informatics technology, across their development lifecycle, in an effort to address priority needs in immune-mediated or infectious disease research.
Understanding the mechanisms of how bats regulate immune responses to clear infections and prevent excessive inflammation may lead to a deeper understanding of the regulatory circuitry of the human immune system and host-pathogen interactions.
As part of UNITE, an NIH initiative to end structural racism in biomedical research, the Center for Scientific Review continues to take steps to address individual and systemic biases in peer review.
NIH launched the Rapid Acceleration of Diagnostics initiative to quickly develop, commercialize, and implement technologies for COVID-19 testing. You can now view a list of funded projects.
NIH is collecting community feedback on developing 3D cellular senescence maps in mice to inform the role of cellular senescence in health and disease and the consequences of interventions targeting this process.
Our expert panel will consider three topics related to ethical, legal, and social implications of big data and frame issues for the immune-mediated and infectious disease research community to consider and address.
For each stage of the grant application process, well-timed guidance from the appropriate NIH or NIAID expert can help you meet requirements, get advice, and more.
NOT-OD-21-091, Notice of Special Interest (NOSI)—Administrative Supplements To Support Enhancement of Software Tools for Open Science
NOT-OD-21-089, Notice of Special Interest—Support for Existing Data Repositories To Align With FAIR and TRUST Principles and Evaluate Usage, Utility, and Impact
RFA-AI-21-019, Radiation-Induced Immune Dysfunction (U01, Clinical Trial Not Allowed)
RFA-AI-21-012, Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61/R33, Clinical Trial Not Allowed)
RFA-AR-21-015, Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases—Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjgrens Syndrome (UC2, Clinical Trial Optional)
RFA-AR-21-016, Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases—Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2, Clinical Trial Not Allowed)
RFA-AI-21-025, Prevention Strategies To End the HIV Epidemic (R01, Clinical Trial Optional)
RFA-AI-21-024, Multidisciplinary Treatment Approaches To End the HIV Epidemic (R01, Clinical Trial Optional)
RFA-AI-21-023, Respond—Epidemiology To End the HIV Epidemic (RESPOND—EEE) (R01, Clinical Trial Optional)
RFA-AI-21-009, Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01, Clinical Trial Not Allowed)
RFA-LM-21-001, NLM Institutional Grants for Research Training in Biomedical Informatics and Data Science (T15, Clinical Trial Not Allowed)
RFA-MD-21-004, Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01, Clinical Trial Optional)
NOT-AI-21-032, Notice of Special Interest (NOSI)—Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies
NOT-OD-21-062, Notice of Special Interest (NOSI)—Administrative Supplement for Providing Technical and Business Assistance (TABA) Funding to SBIR/STTR Awardees (Admin Supp)
NOT-OD-21-068, Notice of Special Interest (NOSI) To Add Harassment as an Area of Interest to Research To Understand and Inform Interventions That Promote the Research Careers of Individuals in the Biomedical Sciences
PAR-21-184, Research on Bat Immunology (R21, Clinical Trial Not Allowed)
PAR-21-169, Support for Research Excellence (SuRE) Award (R16, Clinical Trial Not Allowed)
PAR-21-173, Support for Research Excellence First Independent Research (SuRE-First) Award (R16, Clinical Trial Not Allowed)
RFA-DK-21-004, The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01, Clinical Trial Optional)
RFA-AI-21-035, Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-Mediated Diseases (R21, Clinical Trial Not Allowed)
RFA-AI-21-021, Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated Diseases (U24, Clinical Trial Not Allowed)
RFA-AI-21-020, Early-Stage Development of Data Science Technologies for Infectious and Immune-Mediated Diseases (U01, Clinical Trial Not Allowed)
PAR-21-109, Early-Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21, Clinical Trial Not Allowed)
This email was sent to rssproject471@gmail.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107
Belum ada tanggapan untuk "NIAID Funding News, April 7, 2021"
Post a Comment